Dr. Davies on Personalizing Treatment in Relapsed/Refractory Myeloma

Video

Faith E. Davies, MD, shares advice on how to best treat patients with relapsed/refractory multiple myeloma.

Faith E. Davies, MD, a professor in the Department of Medicine and director of the Clinical Myeloma Program at NYU Langone Health’s Perlmutter Cancer Center, shares advice on how to best treat patients with relapsed/refractory multiple myeloma.

Patients with relapsed/refractory multiple myeloma should be monitored closely, says Davies. It is also important to be proactive when patients relapse, to remember that a wrong answer does not exist, and that each patient is different, adds Davies. Knowing what treatment patients have received before, what adverse events they had from that treatment, and what problems they have now will allow for personalized therapy for each individual patient; this will ensure that patients are given the best treatment possible at that particular point in their treatment journey, concludes Davies.

Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Francesco Di Meo, PhD
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Danai Dima, MD
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ariel Grajales-Cruz, MD, assistant member, Department of Malignant Hematology, Multiple Myeloma Section, Moffitt Cancer Center; assistant professor, University of South Florida
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center